East Tennessee State University

Digital Commons @ East
Tennessee State University
Electronic Theses and Dissertations

Student Works

5-2015

Effects of Select Vitamin E Isoforms on the
Production of Polyunsaturated Fatty Acid
Metabolites in Colorectal Cancer
Martha A. Borketey
East Tennessee State University

Follow this and additional works at: https://dc.etsu.edu/etd
Part of the Chemistry Commons
Recommended Citation
Borketey, Martha A., "Effects of Select Vitamin E Isoforms on the Production of Polyunsaturated Fatty Acid Metabolites in Colorectal
Cancer" (2015). Electronic Theses and Dissertations. Paper 2480. https://dc.etsu.edu/etd/2480

This Thesis - Open Access is brought to you for free and open access by the Student Works at Digital Commons @ East Tennessee State University. It
has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Digital Commons @ East Tennessee State
University. For more information, please contact digilib@etsu.edu.

Effects of Select Vitamin E Isoforms on the Production of Polyunsaturated Fatty Acid
Metabolites in Colorectal Cancer
___________________________________
A thesis
presented to
the faculty of the Department of Chemistry
East Tennessee State University

In partial fulfillment
of the requirements for the degree
Master of Science in Chemistry
________________________________
by
Martha Akuorkor Borketey
May 2015
________________________________
Dr. Sharon Campbell, Chair
Dr. William Stone
Dr. Cassandra Eagle

Keywords: Polyunsaturated fatty acids, hydroxyeicosatetraenoic acids,
hydroxyoctadecaenoic acids, alpha tocopherol, gamma tocopherol, gamma tocotrienol,
alpha-gamma tocopherol mixture

ABSTRACT
Effects of Select Vitamin E Isoforms on the Production of Polyunsaturated Fatty Acid
Metabolites in Colorectal Cancer
by
Martha Akuorkor Borketey

Vitamin E exhibits anti-tumor activity by regulating pathways in cancer cells, potentially
the lipoxygenase (LOX) pathway. We studied the effects of alpha tocopherol (AT),
gamma tocopherol (GT), gamma tocotrienol (GT3), and an alpha-gamma tocopherol
mixture (ATGT) on the production of the LOX metabolites 13-hydroxyoctadecaenoic
acid (HODE), 15-hydroxyeicosatetraenoic acid (HETE), 12-HETE, and 5-HETE in
colorectal cancer. These metabolites were examined in the HCT-116 cell line after 24 h
treatment with select vitamin E isoforms and quantified by LC/MS/MS. Under
physiological conditions, we find that treatment with varying vitamin E isoforms have
different effects on the production of 13-HODE, 15-HETE, 12-HETE, and 5-HETE. GT
increases 13-HODE and decreases 12-HETE. AT reverses the effects of GT regulation
on the LOX pathway, while GT3 has no significant effect on the metabolites tested. GT
shows superiority in regulating the LOX pathway as it increases 13-HODE and
decreases 12-HETE for possible prevention of colorectal cancer.
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CHAPTER 1
INTRODUCTION
Mechanisms of Cancer Development
Cancer is a disease consisting of a mass of cells that grow and divide faster than
normal cells of the corresponding tissue type. Some features of cancer cells include the
fact that they are poorly differentiated compared with normal cells. Cancer cells also
have the ability to metastasize as compared to normal cells which are confined to their
position within an organ by cell adhesion molecules1.
The development of cancer involves multiple processes which are marked by
four successive stages: initiation, promotion, progression and malignancy2. The first
stage, initiation, often occurs as a result of continual deoxyribonucleic acid (DNA)
damage by reactive oxygen species (ROS) such as hydrogen peroxide, superoxide
radicals, and hydroxyl radicals. These ROS are produced by exogenous and
endogenous sources such as environmental pollutants, radiation (e.g. X-rays, ultraviolet
light (UV) light and gamma rays), metals (i.e. by Fenton reactions), activation of
inflammatory cells (e.g. macrophages and neutrophils), cytochrome P450 enzyme
etc2,3,4. Mutations to genes can result in the formation of oncogenes and the loss of
function of tumor suppressor genes5 which may be prevented, in part, by antioxidant
intake. Tumor suppressor genes are genes that hinder the proliferation of cells.
Malfunction or inactivation of these genes can promote carcinogenesis6. Inactivation of
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tumor suppressor genes occurs through mechanisms such as point mutations (change
of a single nucleotide in DNA) or deletions7.
Oncogenes are genes that are formed as a result of mutations in protooncogenes (i.e. proteins that regulate cell proliferation)8. Oncogenes can be activated
by mechanisms such as gene amplification (i.e. production of several copies of a gene
due to continuous replication of a section of the DNA), point mutation and chromosome
rearrangements or translocations (i.e. attachment of a section of chromosome to a
different chromosome)9,7. These mutations cause proto-oncogenes to be more highly
expressed in cells than normal which enhance carcinogenesis10,1,11.
Promotion, the second stage of cancer development, involves proliferation of the
altered cells to produce benign tumors resulting from group of compounds called
promoters2. Progression and malignant stages in carcinogenesis occur when some of
these benign tumors further develop to form invasive tumors7,2.
Carcinogenesis occurs due to a malfunctioning of genes that usually regulate the
growth and proliferation of cells which leads to continual progression of the cell
cycle7. Alterations of genes that control the checkpoints of the cell cycle from Gap1
(G1) to S (DNA synthesis) or from Gap 2 (G2) to Mitotic (M) phase may cause cells to
rapidly divide (enhance cell proliferation) or may cause cells to refuse to undergo
apoptosis. Mutations in these checkpoint genes arise in many human cancers 12. These
genes include cyclins, retinoblastoma gene (RB), p53 gene, cyclin-dependent kinases
(cdks)7, etc.
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Cyclin-dependent kinase 4 (Cdk4) and cyclin D1 complex (proto-oncogenes) are
also genes that control the G1 phase. These genes phosphorylate RB causing the
continuation of the cell cycle in normal cells1. The over expression of cyclin D1 or Cdk4
enhance cell proliferation and are observed in various human cancer cells including
breast cancer13.
RB is a tumor suppressor gene that is hypophosphorylated in the initial stages of
G1 and bonds to E2F proteins, nullifying E2F activity by joining to promoter genes in
which the E2F/DP complex bind. The E2F/DP complex regulates proteins involved in
the development of the cell cycle such as cyclins and cdks. When RB is
hypophosphorylated, it inhibits the untimely production of genes that control the cell
cycle1, 7 and allows for DNA replication. Functional RB protects the fidelity of the DNA
by preventing DNA replication of mutated DNA. Dysfunction of the RB gene results in
replication of mutated DNA which creates genetic instability and allows for uncontrolled
cell proliferation in several cancers13. Defects in the RB gene in germ line cells can also
cause familial RB cancers7.
The p53 gene is another tumor suppressor gene which functions as a proapoptotic gene by preventing multiple mutations from being integrated into DNA, by upregulating apoptotic proteins that cause the death of the cells when severe DNA
damage occurs1. Malfunctioning of the tumor suppressor gene p53 prevents apoptosis
from occurring and leads to an increase in mutations, which enhances the development
of cancer. Apoptosis is a process that allows organisms to control the number of cells
in a tissue by removing cells that are aged or damaged12. The significance of apoptosis
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in the development of cancer is observed when mutated cells continue to proliferate
instead of dying12. The refusal of cancer cells to undergo apoptosis plays a significant
role in the progression of tumors14.
The p16 gene is a tumor suppressor gene whose function is to hinder the
continuation of the cell cycle when cells are damaged by inhibiting the activity of cyclin
D1 and Cdk4 complex. A defect in the p16 gene is observed in many human cancers.
Mutations in other genes (e.g. p15 and p18) that inhibit the production of cyclin D1 and
Cdk4 complex are also observed in various human cancers13,12. However, over
expression of B-cell lymphoma 2 (bcl-2) protein, an anti-apoptotic protein, impedes
apoptosis and enhances the survival of cancer cells1.
Carcinogenesis may also occur as a result of poor differentiation of cells. Cell
differentiation is the process by which specialized cells are formed from non-specialized
stem cells. These specialized, differentiated cells generally perform the work of tissues
in an organism. Tumors may develop as a result of incomplete differentiation of these
stem cells, which may occur as a result of mutations in their DNA, or dedifferentiation of
fully differentiated cells. Accumulation of mutations in cells may prevent cells from
undergoing complete differentiation which could lead to cancer development 12,1,15.
The carcinogenesis process is influenced by environmental and hereditary
factors16. Hereditary factors typically range from 5% to 10% of all cancers while
environmental factors account for 90% to 95% of cancers17. Environmental factors
include obesity, poor nutrition, physical inactivity, radiation, tobacco usage, and
exposure to pollutants from the environment17.
19

Colorectal Cancer and its Risk Factors
Colorectal cancer is ranked as the third most common cancer in both males and
females16. In 2014, approximately 136,830 colorectal cancer cases with 50,310 deaths
are anticipated to occur in the United States. Colorectal cancer risk increases with age
and 90% of colorectal cancer cases are identified in people who are 50 years and older.
Alcohol intake, chronic smoking, lower intake of fruits and vegetables as well as a diet
rich in meat (red or processed) are environmental factors that enhance the risk of
developing colorectal cancer16.
Tobacco smoking is a major cause of cancer worldwide18. More than 60
carcinogens have been confirmed to be present in cigarette smoke19. These include
aldehydes, volatile organic hydrocarbons, N-nitrosamines, aromatic amines, metals,
and polycyclic aromatic hydrocarbons (PAHs). Among these, the major carcinogens in
human cancers are N-nitrosamines, aromatic amines, and PAHs19. The relationship
between tobacco products and cancer development in humans is due to the presence
of these carcinogens20,21. Cancer associated with tobacco consumption includes
bladder, lung, stomach, kidney, colorectal, and pancreatic cancers18. It has been shown
that smokers have a greater risk of developing colorectal cancer compared with nonsmokers22. In addition, the risk of developing colorectal cancer is linked to the number
of years of cigarette smoking22.
Cigarette smoke extract enhances the growth of colorectal tumors by upregulating the expression of cyclooxygenase-2 (COX-2) and 5-LOX proteins as well as
their metabolites prostaglandins E2 (PGE2 ) and leukotriene B4, in colorectal tumors23.
20

Nicotine, a primary constituent of cigarettes increases cell proliferation in human
colorectal cancer cell lines24. These findings indicate that tobacco constituents play a
critical role in colorectal tumorigenesis.
Dietary factors have also been associated with colorectal cancer development.
For example, high intake of fruits (e.g. banana, fruit juice, pear, citrus fruits, and apple)
and vegetables (e.g. spinach, tomato, carrot, cabbage) are inversely linked to colorectal
cancer development25. The intake of fruit fiber is also shown to be inversely linked to
the risk of developing colorectal cancer26.
However, a high intake of red (e.g. lamb, beef and pork) and processed meat
(e.g. corned beef, chicken, ham, sausages, bacon etc.) is reported to be significantly
linked to enhanced risk of colorectal cancer development27,26. Animal fat including
monounsaturated fat and saturated fat is positively linked to the risk of developing
colorectal cancer26. In addition, a significant inverse link is observed between
polyunsaturated fatty acids and colorectal cancer development28.
The Role of Polyunsaturated Fatty Acid Metabolites and Their Enzymes in Cancer
Bioactive products such as PGs, HETEs, and HODEs produced through the
metabolism of arachidonic acid (AA) and linoleic acid (LA) by LOX and COX enzymes
are associated with carcinogenesis29,30,31.
COX enzymes metabolize AA to produce thromboxane A2 (TXA2 ) and PGs (D2
and E2)32. LOX enzymes also metabolize AA to produce hydroperoxyeicosatetraenoic
acids, which are subsequently reduced to form HETEs. The main LOX enzymes
21

present in humans are 15-LOX, 5-LOX, and 12-LOX which metabolize AA to produce
15-HETE, 5-HETE, and 12-HETE, respectively33,34. 15-LOX also metabolizes LA to
produce 13-HODE and 9-HODE34. Production of LOX and COX metabolites are
illustrated in Figures 1, 2, and 335,36.
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Figure 1. The production of TXA2, PGD2, and PGE2 through the metabolism of AA by COX enzymes
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Figure 2. The production of 15-HETE, 12-HETE, and 5-HETE through the metabolism of AA by LOX
enzymes 15-LOX-1, 12-LOX, and 5-LOX respectively
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Figure 3. The production of 13-HODE through the metabolism of LA by 15-LOX-1 enzymes
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A number of studies indicate that COX and LOX pathways play important roles in
cancer development37,38. For instance, COX-2 is highly expressed in various tumors
including prostate and colorectal tumors39,37,40. Also, 12-LOX and its metabolite12HETE are shown to be highly expressed in colorectal tumors compared with the normal
colorectal tissue, indicating that over expression of the 12-LOX pathway enhances
colorectal carcinogenesis41,42,43. High levels of 12-HETE in colorectal cancer cells
enhances cell proliferation which is important to colorectal cancer development41,44.
Hence, inhibiting the production of 12-HETE may slow proliferation in colorectal cancer
cells. This was demonstrated when the reduction of 12-HETE production by sulindac (a
non-steroidal anti-inflammatory drug (NSAID) decreased the colon tumor growth in
Fischer 344 rats42. Also, a decrease in 12-HETE production by baicalein (a 12-LOX
inhibitor) hindered cell proliferation in Caco-2 human colon cancer cells44. These
studies indicate that, blocking the 12-LOX pathway is important in preventing colorectal
cancer development.
In addition to colorectal cancer cells, 12-LOX is also shown to be highly
expressed in prostate cancer cells45,46. This was demonstrated in a study that analyzed
the expression of 12-LOX in the cancer and normal tissue collected from the prostate of
122 prostate cancer patients. Approximately half of prostate cancer patients had high
levels of 12-LOX in their prostate cancer tissues compared to their corresponding
normal prostate tissues, suggesting that 12-LOX may contribute to the progression of
prostate tumors45. Blocking 12-LOX pathway by its inhibitors (i.e. N-benzyl-N-hydroxy5-phenylpentamide (BHPP) and baicalein) was shown to enhance apoptosis, decrease
cell proliferation and cause cell cycle arrest in prostate cancer cells (DU-145 and
24

PC3)46. It was observed that BHPP and baicalein inhibited about 50% of DU-145 and
PC3 cells from proliferating in a concentration dependent manner (5–50 µM).
Subsequently, inhibition of 12-LOX results in cell cycle arrest as observed by an
increase in the number of cells in G0/G1 phase, a decreased expression of G1 phase
proteins (Cdk2/4 and cyclins D1 and D2), a decrease in cell number in S phase and G2M phase, and decreased expression of the anti-apoptotic protein, bcl-246. These results
indicate that 12-LOX plays an important role in enhancing cell proliferation and
preventing apoptosis in prostate cancer and hence, blocking this pathway may be
important in suppressing both prostate and colon cancer development. 12-LOX and its
metabolite 12-HETE is also expressed in other cancer cell lines such as W256 cells (a
rat Walker carcinoma cells)31,43. In the W256 cells, it was observed that treatment with
the 12-LOX inhibitor, BHPP hindered cell growth31. These studies suggest that blocking
the 12-LOX pathway may result in suppressing tumorigenesis in various tissue types.
5-LOX is also linked to cancer development38,47. For example, 5-LOX is highly
expressed in colorectal tumors as compared with normal colorectal tissues48,47. Higher
levels of 5-HETE, a 5-LOX metabolite are reported in colorectal cancer cells44,42. These
observations suggest that the 5-LOX pathway may also enhance colorectal
tumorigenesis. It is observed that the treatment of colorectal cancer cells (Caco-2 and
LoVo cells) with 5-LOX inhibitors (1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]α,α-dimethyl-5-(1-methylethyl)-1H-indole-2-propanoic acid (MK 886) and α-pentyl-3-(2quinolinylmethoxy)-benzenemethanol (Rev5901)) decrease the proliferation of the cells,
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indicating that colorectal carcinogenesis may be suppressed as the 5-LOX pathway is
blocked44,47.
In addition to colorectal cancer cells, high levels of 5-HETE are present in the
prostate cancer cells PC3 and LNCaP38. The presence of 5-HETE enhances cell
proliferation in these prostate cancer cells suggesting the key role for 5-HETE in
prostate cancer development49. Treatment of PC3 and LNCaP cells with 5-LOX
inhibitors (MK886 and 2-(12-Hydroxydodecane-5, 10-diynyl)-3, 5, 6-trimethyl-pbenzoquinone (AA861)) induces apoptosis and inhibits cell growth49,38 indicating that,
the 5-LOX pathway is essential in prostate cancer progression.
13-HODE, another metabolite of LOX enzymes is produced when LA is
metabolize by the15-LOX-1 enzyme50. Higher levels of 13-HODE are found to be
present in normal colorectal tissues compared with colorectal cancer tissue51,52,
suggesting a protective effect of 13-HODE against colorectal cancer. 15-LOX-1, the
enzyme which metabolizes LA to produce 13-HODE, is reduced in colorectal tumors
compared with normal colorectal tissues, indicating that loss of 15-LOX-1 expression
enhances colorectal tumorigenesis52.
13-HODE plays a significant role in preventing colorectal cancer progression by
inducing apoptosis, reducing cell proliferation, and inhibiting the continuation of the cell
cycle in colorectal cancer cells (RKO and HT-29 cells)52. These results indicate that 13HODE up regulation suppresses colorectal tumorigenesis. As a result NSAIDs such as
sulindac, sulindac sulfone, and N-[2-(cyclohexyloxy)-4-nitrophenyl]-methanesulfonamide
(NS-398) have been found to increase 13-HODE production as well as 15-LOX-1
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expression in colorectal cancer cell lines (DLD-1, RKO, and HT-29 cells)53,54. Apart
from colorectal cancer cells, the level of 13-HODE production in esophageal, breast,
and lung cancer cells is also reduced compared with their normal cell
counterparts55,56,57, suggesting that 13-HODE formation is crucial in suppressing the
development of these cancers.
LOX metabolites have been identified as endogenous ligands of peroxisome
proliferator-activated receptor γ (PPAR γ)58,59. PPAR γ is a nuclear receptor identified to
be highly present in adipose tissues and controls adipocyte differentiation60. PPAR γ is
also seen to be highly expressed in cancer cells such as colon, breast, bladder and
prostate cancers61,62,63,64,65. Ligand activation of PPAR γ causes differentiation, hinders
cell proliferation, and enhances apoptosis of cancer cells65,61,62. PPAR γ is activated by
synthetic ligands such as thiazolidinediones (e.g. rosiglitazone (BRL 49653) and
troglitazone)61 and endogenous ligands such as 15-HETE, 13-HODE and 9-HODE66,59.
In colorectal cancer cells (Moser and HT-29 cells), it is reported that ligand
activation of PPAR γ by 15-deoxy-delta-12, 14-prostaglandin J2 , BRL49653, and
troglitazone reduces cell proliferation, enhances cell differentiation, and impedes G1
cycle progression61,65. In breast cancer cells (MCF7), ligand activation of PPAR γ by an
all trans-retinoic acid and troglitazone mixture decreases the tumor volume of MCF7
cells in mice and enhances apoptosis in MCF7 cells observed by a reduction in bcl-2
protein expression62. PPAR γ activation by 15-HETE reduces cell proliferation in
prostate cancer cells66. These findings suggest that up regulating endogenous PPAR γ
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ligands such as 13-HODE could repress the progression of cancers such as colon,
esophageal, breast, and lung cancer, which have decreased levels of 13-HODE.
15-HETE, a 15-LOX-1 metabolite is also identified in colorectal cancer
tissues44,67. Higher levels of 15-HETE are shown to be present in colorectal tumors
compared with the normal colorectal tissues42,44. The presence of 15-HETE in
colorectal cancer cells (Caco-2 cells) has also been demonstrated to enhance the
growth of the cells, indicating that high levels of 15-HETE may enhance colorectal
carcinogenesis44.
Vitamin E and its Role in Cancer Development
Vitamin E is a family of compounds that include isoforms of tocopherols and
tocotrienols. Tocotrienols and tocopherols have four different isoforms that vary from
each other by the number and arrangement of methyl groups on the chromanol head.
These isoforms include alpha, beta, gamma, and delta68. Both families of compounds
possess a chromanol head with tocopherol having a phytyl tail and tocotrienols having
an isoprenoid tail69. Vitamin E is obtained from nuts, vegetable oil, and grains70. The
structures of the different vitamin E isoforms are shown in Figure 471.
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Figure 4. The structure of tocopherols and tocotrienols. Alpha isoform when R1 and R2 represent CH3 and
CH3, beta isoform when R1 and R2 represent CH3 and H, gamma isoform when R1 and R2 represent H and
CH3, delta isoform when R1 and R2 represent H and H

Vitamin E is recognized by its ability to function as an antioxidant by donating its
phenolic hydrogen to primarily quench peroxyl radicals, as well as other ROS such as
hydroxyl radicals etc., and hence prevent these ROS from attacking lipids, proteins, cell
membranes, and nucleic acids (e.g. DNA)72,73,4,2. Scavenging of these ROS by vitamin
E may prevent continual DNA damage which could lead to cancer initiation3,4.
A number of studies have shown an inverse link between vitamin E and the risk
of developing cancer. For example, it has been reported in a study that mice fed 600
mg of vitamin E (form not specified, but likely all-rac-alpha-tocopheryl acetate) per
kilogram of diet, the vitamin E group developed low number of colon tumors compared
to a non-vitamin E-supplemented group74. It has also been reported that high amounts
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of AT in human serum is associated with a reduced risk of developing gastric cancer75.
A mixture of synthetic vitamin E (all-rac-alpha-tocopheryl acetate) and lycopene (5
mg/kg body weight each) has also been shown to reduce the growth of prostate tumors
as well as enhance the survival of the mice in a PC-346C mouse xenograft model76.
Alpha-tocopheryl succinate (2-20 µM), a synthetic vitamin E ester has also been
reported to decrease proliferation and cause cell cycle arrest in prostate cancer cells
(LNCaP cells). Cell cycle arrest in LNCaP cells was observed by an increase in the
number of cells in G1 phase and a decrease in cell number in S and G2 phase. In this
same study, a decrease in the expression of cycle proteins such as cdk4, cdk2, cyclin
D3, cyclin D4, and cyclin E (G1/S proteins) was observed after treating the LNCaP cells
with alpha-tocopheryl succinate77. Over expression of the proteins cdk4, cdk2, cyclin,
D3 cyclin D4, and cyclin E enhances cell proliferation, hence, a decrease in these
proteins by alpha tocopheryl succinate would impede progression in LNCaP cells.
These findings suggest that vitamin E esters exhibit anti-cancer properties and may play
a significant role in suppressing cancer development.
Although a majority of studies conducted with vitamin E in relation to cancer
prevention have been performed with AT or AT derivatives75,76,16,77, GT exhibits better
anti-cancer activity than AT. For example, GT is shown to decrease human breast and
mammary tumors (MDA-MB-231-GFP and 66cl-4-GFP cells) and induce apoptosis in
mice, while neither AT nor a mixture of AT and GT had any effect on the tumor volume
nor induced apoptosis in these mice78,79.
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In colorectal cancer cell lines (HCT-116, HT-29, and CaCo-2 cells), GT
decreases cell proliferation better than AT80,81. It was observed that GT significantly
causes cell death at a concentration as low as 25 µM while AT only results in cell death
at a concentration of 200 µM compared to the control. GT also induced apoptosis in
HCT-116 and SW480 cells better than AT81. GT has also been shown to increase
PPAR γ expression better than AT in SW480 cells colorectal cancer cells82.
In the LNCaP and DU-145 cells prostate cancer cells, 25 µM GT was shown to
effectively reduce cell proliferation compared to 25 µM AT. In this study, GT causes
more than a 70% decrease in cell proliferation while AT causes about a 50% reduction
in proliferation80. GT decreases the cell proliferation in PC-3 cells as well as the
expression of cyclin D1, D3, and E (G1 check point proteins) in prostate cancer cell lines
PC-3, LNCaP, and DU-14580,83. Over expression of the proteins cyclin D1, D3, and E
mediates cell proliferation. Hence a decrease in these proteins by GT would impede
the progression of the cell cycle at G1 phase and hence slow proliferation of the prostate
cancer cells80,83.
These findings suggest that GT regulates pathways in cancer cells such as cell
proliferation, cell cycle, and apoptosis in order to suppress cancer progression. These
findings, also demonstrate that GT is more potent than AT in regulating these pathways
(i.e. cell proliferation, cell cycle and apoptosis) to prevent cancer development.
GT3, an isoform of vitamin E containing an isoprenoid tail, has demonstrated
potent anti-cancer potential. For example, in MCF-7 and MDA-MB 231 breast cancer
cells both α-tocotrienol (AT3) and GT3 hindered proliferation of the cells in a
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concentration dependent manner (10-40 µM)84. However, the proliferation of the cells in
GT3-treated sample was less than the proliferation in the AT3-treated cells suggesting
that GT3 is a more potent anti-cancer agent than AT3. In addition, GT3 decreases G1
phase check proteins such as CdK4 and cyclins D1/D3 in MCF-7 cells which indicates
that GT3 can cause cell cycle arrest at G1 phase84.
In other cancer tissue types such as the human cervical cancer HeLa cell line,
both AT3 and GT3 decrease cell proliferation with GT3 showing a greater inhibitory
effect than AT385. Both AT3 and GT3 also impede the progression of the cell cycle in
HeLa cells as observed by an increase in the number of cells in G0/G1 phase and
decrease in cell number in the S phase85.
Finally, in the RKO colorectal cancer cell line, the tocotrienol-rich fraction
consisting of a mixture of AT, beta tocopherol (BT), and GT isoforms hinders cell
growth, induces apoptosis, causes cell cycle arrest at G1, and increases the expression
of p53 proteins in the RKO cells86. These studies indicate that tocotrienols also regulate
various pathways such as cell cycle, cell proliferation, and apoptosis in cancer cells to
prevent cancer progression. In addition, these studies suggest that GT3 exhibits
greater anti-cancer activity than AT3.
Based on these observations, vitamin E (tocopherols and tocotrienols) can be
said to exhibit anti-tumor activity by regulating various pathways in cancer cells such as
cell proliferation and apoptosis. These studies also suggest that the development of
colorectal cancer is enhanced by low production of 13-HODE and high production of 15HETE, 12-HETE, and 5-HETE. Therefore, we hypothesize that vitamin E (tocopherols
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and tocotrienols) can increase the production of 13-HODE and decrease the production
of 15-HETE, 12-HETE, and 5-HETE in colorectal cancer cells.
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CHAPTER 2
METHODS
Cell Culture
Human colon cancer cells (HCT-116 cell line) were cultured in McCoy’s 5A
media which is enriched with 10% fetal bovine serum (FBS) and 50 IU
penicillin/streptomycin in an environment with 5% carbon dioxide at 37 ºC83.
Determination of Concentrations of AT, GT, GT3, and a Mixture of Alpha (5%) and
Gamma Tocopherol (95%)(ATGT)
The concentrations of AT, GT, GT3, and ATGT were determined using an HP8542A diode array spectrophotometer. The wavelength of maximum (max) absorbance
(λmax) for GT, GT3, and ATGT is 298 nm and that of AT is 292 nm. The molar
absorptivity (ε) for GT and ATGT is 3810, AT is 3270, and GT3 is 4230. The BeerLambert Law was used to calculate the concentration of the vitamin E isoforms using
the absorbance and the ε at the appropriate λmax83.
Sample Preparation for Liquid Chromatography Mass spectrometry Analysis
(LC/MS/MS)
Treatment of Cells. HCT-116 cells were seeded at a concentration of 2.5 x 106 in
a T-75 mL flask or 10 mm round dishes for 24 hours before treatment. The cells were
then treated with 5 µM of AT, GT, GT3, and ATGT for 24 hours. The untreated cells
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(vehicle) were also prepared with a volume of ethanol corresponding to the volume of
vitamin E added for 24 hours83.
Extraction of Fatty Acid Metabolites from Cells. After 24 hours of treatment, the
media was removed from the cells and stored in a -80 ºC freezer for a period of no
longer than 1 week before the analysis was performed. The cells were harvested with 5
mL of trypsin (0.25%) with balanced salts (Hyclone SH30042.02) and collected by
centrifugation. The cell pellet was washed with 5 mL of phosphate buffered saline
(PBS), and collected by centrifugation. The cells were re-suspended in 500 µL of PBS
with 1 mM calcium chloride solution and incubated at 37ºC for 2 minutes87. As
previously described, an aliquot 2.5 µL of calcium ionophore A23187 (1 mM) was added
to the mixture, followed by addition of 100 µM of AA87. The ionophore in this reaction
will demonstrate the activity of the LOX pathway, and in the presence of additional
substrate (AA) it will show that the LOX enzyme is still active upon production of
metabolite. The reaction mixture was incubated at 37ºC for 10 minute under minimal
light87. After incubation, the cells were then collected by centrifugation. Using an
enzyme-linked immunosorbent assay (ELISA) assay (Enzo Life Sciences, Farmingdale,
NY) according to the manufacturers’ protocol, the cell pellets were then washed with 1
mL of ice cold PBS, and recollected by centrifugation. The cells were lysed with ice
cold lysis buffer (200 µL) and acidified to pH 3.5-4.0 with 0.2 N HCl. The fatty acid
metabolites were extracted from the reaction mixture three times using a 3-fold excess
of ethyl acetate. The upper layer (organic phase) were collected into a fresh tube and
dried under a stream of nitrogen gas. The dried samples were stored in a -80 ºC freezer
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no longer than one week before analysis was performed. The dried samples were
dissolved in 100 µL of methanol and filtered for LC/MS/MS analysis immediately before
analysis.
Extraction of Fatty Acid Metabolites from Media. A solid phase extraction (SepPak) cartridge was conditioned with methanol and equilibrated with water under gravity,
then loaded with 3 mL of sample. The column was then washed with 3 mL of the
following solvents, water, 15% ethanol, and hexane. Following the washes, 1 mL of
methanol was added to the cartridge and centrifuged for 10 minutes to collect the
analytes. The eluent containing the analytes was dried under nitrogen gas and stored
in a -80ºC freezer no longer for a period of one week before analysis. Just prior to the
analysis, the dried sample was dissolved in 100 µL of methanol and filtered for
LC/MS/MS analysis88.
Analysis of Fatty Acid Metabolites Using Gradient LC/MS/MS
Separation and detection of metabolites was achieved using the Shimadzu ITTOF (ion trap-time of flight) LC/MS/MS with an ultrasphere C18 4.6 mm * 250 mm
column (5µm, Beckman)89. Mobile phase A contains 30% acetonitrile/70% 0.1% formic
acid in water and mobile phase B contains of 0.1% formic acid in acetonitrile. Mobile
phase A and B were delivered at a flow rate of 0.5 mL/min with the following gradient:
75-90% B in 10 min: 90% B in 2 min: 75 % B in 5 min. The volume of sample injected
was 10 µL and the column temperature was kept at 40ºC. The metabolites were
detected with the Shimadzu IT-TOF mass spectrometer (Columbia, MD), which is run in
electrospray negative mode with a source temperature of 200ºC. The metabolites were
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identified based on their m/z ratios and their retention times. The m/z of HETEs (12HETE, 15-HETE, and 5-HETE) was 319.22 and 13-HODE was 295.2289. All samples
and external standards (12-HETE, 15-HETE, and 5-HETE prepared standards) were
analyzed in duplicate.
Sample Preparation for ELISA Analysis
Treatment of Cells. HCT-116 cells were cultured to about 50-75% confluence.
The cells were then treated with 5 µM of GT, AT, ATGT, or GT3 for 24 hours. The
untreated cell (vehicle) was also prepared for 24 hours.
Extraction of Fatty Acid Metabolites. The treated cells were harvested with 5 mL
of trypsin (0.25%) with balanced salts (Hyclone SH30042.02) and collected by
centrifugation. The resulting cell pellets were washed in 5 mL of PBS. The cells were
counted with a hemocytometer and a total of 10 million cells collected by centrifugation
and were resuspended in 500 µL of PBS with 1 mM calcium chloride solution and
incubated at 37 ºC for 2 minutes87. An aliquot of 2.5 µL of calcium ionophore A23187 (1
mM) was added to the mixture, followed by addition of 100 µM of AA87. The reaction
mixture was incubated at 37 ºC for 10 minutes at minimum light87. After incubation, cells
were collected by centrifugation. Using an ELISA assay (Enzo Life Sciences,
Farmingdale, NY) according to the manufacturers’ protocol, cell pellets were then
washed with 5 mL of ice cold PBS, and recollected by centrifugation. The cells were
lysed with 200 µL of ice cold lysis buffer and the lysate was acidified to pH 3.5-4.0 with
0.2 N HCl. The fatty acid metabolites were extracted from the reaction mixture three
times using 3-fold excess of saturated ethyl acetate. The upper layer (organic phase)
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were collected into a fresh tube and dried under nitrogen gas. The dried samples were
stored in -80 ºC freezer for a period of no longer than one week before prepared for
analysis by dissolving them in 44 µL of ethanol and 176 µL of assay buffer.
Analysis of Fatty Acid Metabolites Using ELISA
The amount of 13-HODE in HCT-116 cells were analyzed using an ELISA assay
(Enzo Life Sciences, Farmingdale, NY) according to the manufacturers’ protocol. The
optical density was read at 405 nm with ultraviolet-visible (UV-VIS) spectrophotometer
plate reader (Molecular Devices, Spectra Max Plus 384).
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CHAPTER 3
RESULTS
LC/MS/MS Chromatogram for Fatty Acid Metabolites in HCT-116 Cells
The amount (nmoles) of 12-HETE, 5-HETE, 15-HETE, and 13-HODE in the cells
and the media of HCT-116 cell line were determined from the concentrations obtained
from peak areas using the Shimadzu IT-TOF (ion trap-time of flight) LC/MS/MS. The
concentration of 12-HETE, 5-HETE, 15-HETE, and 13-HODE corresponding to each
peak was determined from a calibration graph prepared from a series of standards (0.05
to 4.5 µg/mL). Stock solutions (100 µg/mL) of 12-HETE, 5-HETE, 15-HETE, and 13HODE standards were used to prepare series of standards (0.05 to 4.5 µg/mL) for the
calibration graph. A chromatogram showing the separation of these fatty acid
metabolites in HCT-116 cells is shown in Figure 5. The intensities of the peaks are
measured by the mass spectrometer based on their ion masses to charge ratio (m/z).
The detection of these metabolites is based on their retention time and mass to
charge ratio (m/z). The m/z of HETEs (12-HETE, 15-HETE, and 5-HETE) is 319.22 and
13-HODE is 295.22. The retention times of 13-HODE, 15-HETE, 12-HETE and 5-HETE
are 8.135, 8.22, 8.851 and 9.321 min, respectively. Since the retention time of 13HODE (8.135 min) and 15-HETE (8.22 min) are very close, their identification is made
easier by the mass spectrometry using their molecular weight differences. Mass
spectrometry was chosen as the method of analysis because the concentrations of
these metabolites in the HCT-116 cells are low, ranging from 0.05 - 4.5 µg/mL and
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require a more sensitive instrument for detection. Since the mass spectrometry is
highly sensitive compared to optical methods such as a UV-VIS spectrophotometry90, it
allows the injection of very low sample volume (10 µL) preventing the broadening and
overlapping of peaks.

Figure 5. The chromatogram of fatty acid metabolites (13-HODE, 15-HETE, 12-HETE, and 5-HETE) in HCT116 cells obtained by the Shimadzu LC/MS/MS. This chromatogram represents a 10 µL injection of 4.5 µg/mL
solution of 15-HETE, 12-HETE, 5-HETE, and 13-HODE. The 4.5 µg/mL standard solutions were prepared
from a 100 µg/mL stock solution in ethanol. These metabolites were separated using mobile phase A (30%
acetonitrile/70% 0.1% formic acid in water) and mobile phase B (0.1% formic acid in acetonitrile). Mobile
phase A and B were delivered at a flow rate of 0.5 mL/min with the following gradient: 75-90% B in 10 min:
90% B in 2 min: 75 % B in 5 min
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Amounts of 13-HODE, 15-HETE, 12-HETE, and 5-HETE, Secreted into the Media of
HCT-116 Cells Following Treatment of HCT-116 Cells with GT, AT, ATGT, and GT3.
The metabolites 13-HODE, 15-HETE, 12-HETE, and 5-HETE accumulate in the
cells and then are secreted out of the cells into the extracellular space or the media.
Hence, the amounts of the metabolites (13-HODE, 15-HETE, 12-HETE, and 5-HETE) in
the media of HCT-116 cells were analyzed using the LC/MS/MS method and used as a
measure of metabolite production. The formation of the metabolites and secretion into
the media occur under normal physiological conditions.
The Amount of 13-HODE Secreted into the Media of HCT-116 Cells is Increased by GT
or ATGT but not GT3 nor AT under Physiological Conditions.
13-HODE has been shown to inhibit cell proliferation and induce apoptosis in
colorectal cancer cells52, but the level of 13-HODE in colorectal cancer cells is low
compared to normal colorectal cells51. By increasing the level of 13-HODE, a decrease
in cell proliferation in colorectal cancer cells is possible52. Hence, we decided to
investigate whether GT, ATGT, AT, and GT3 can increase the amount of 13-HODE
secreted into the media of HCT-116 cells.
The treatment of HCT-116 cells with 5 µM GT significantly increases the amount
of 13-HODE as compared with the vehicle in the media of HCT-116 cells (Figure 6; p =
0.038). Under physiological conditions, the amount of 13-HODE secreted into the
media of the GT treated samples is more than a five-fold increase over the vehicle
treated samples.
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Figure 6. The effect of ATGT on the amount of 13-HODE secreted into the media of HCT-116 cells as
analyzed by LC/MS/MS. HCT-116 cells were treated with and without 5 µM ATGT for 24 hours. The lipid
content was isolated from the media and analyzed by LC/MS/MS. The amount of 13-HODE in the media
was determined by stand curve analysis. The amount of 13-HODE in the media of HCT-116 cells treated
with ATGT demonstrate a significant increase over the vehicle-treated cells (n =7; p = 0.045). Statistical
differences were determined by paired t-test. p values < 0.05 were determined statistically significant.
p values are obtained at 95% confidence level. Error bars are representative of SEM of sample.

Some studies have shown that the inclusion of AT with GT decreases the ability
of GT to inhibit cell proliferation and induce apoptosis in cancer cells78. Other studies
demonstrate that AT is less effective at reducing cell proliferation and enhancing
apoptosis in cancer cells78,79,80,81, therefore we investigated the effect of ATGT mixture
on the production of fatty acid metabolites (12-HETE, 5-HETE, 15-HETE, and 13HODE).

The treatment of HCT-116 cells with 5 µM ATGT mixture (95% GT and 5%

AT) under physiological conditions, also increases the amount of 13-HODE significantly
as compared with the vehicle in the media of HCT-116 cells (p = 0.045) as shown in
Figure 7. While the amount of 13-HODE secreted into the media in the ATGT treated
samples was less than a two- fold increase over the vehicle, the 5 µM GT treatment of
HCT-116 cells increases the amount of 13-HODE greater than five-fold over the vehicle
in the media (Figure 6). The decrease in amount of 13-HODE in the ATGT treated
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samples compared with the GT treated samples may be due to the presence of the 5%
AT. This was confirmed when the addition of 5 µM pure AT to HCT-116 cells did not
significantly increase the amount of 13-HODE in the media of HCT-116 cells after
treatment with 5 µM pure AT as compared with the vehicle (Figure 8; p < 0.068),
suggesting that AT does not increase the amount of 13-HODE in the media of HCT-116
cells and that the addition of AT decreases the ability of GT to increase the amount of
13-HODE in the media of HCT-116 cells.

Figure 7. The effect of ATGT on the amount of 13-HODE secreted into the media of HCT-116 cells as
analyzed by LC/MS/MS. HCT-116 cells were treated with and without 5 µM ATGT for 24 hours. The lipid
content was isolated from the media and analyzed by LC/MS/MS. The amount of 13-HODE in the media
was determined by stand curve analysis. The amount of 13-HODE in the media of HCT-116 cells treated
with ATGT demonstrate a significant increase over the vehicle-treated cells (n =7; p = 0.045). Statistical
differences were determined by paired t-test. p values < 0.05 were determined statistically significant. p
values are obtained at 95% confidence level. Error bars are representative of SEM of sample.
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Figure 8. The effect of AT on the amount of 13-HODE secreted into the media of HCT-116 cells as
analyzed by LC/MS/MS. HCT-116 cells were treated with and without 5 µM AT for 24 hours. The lipid
content was isolated from the media and analyzed by LC/MS/MS. The amount of 13-HODE in the media
was determined by stand curve analysis. The amount of 13-HODE in the media of HCT-116 cells treated
with AT cells demonstrated no statistical difference between the AT treated sample compared with the
vehicle treated sample (n = 8; p = 0.068). Statistical differences were determined by paired t-test. p
values < 0.05 were determined to be statistically significant. p values are obtained at 95% confidence
level. Error bars are representative of SEM of sample

While both GT and ATGT significantly increase the amount of 13-HODE in the
media of HCT-116 cells, the amount of 13-HODE secreted into the media of HCT-116
cells did not significantly change following treatment with 5 µM GT3 compared to the
vehicle (Figure 9; p = 0.37). These data (Figures 8 and 9) suggest that neither GT3 nor
AT may be the best isoform of vitamin E to induce an up-regulation of 13-HODE in the
media of HCT-116 cells. Other isoforms of vitamin E such as GT, as well as the
combination of AT and GT (ATGT) should be considered when an increase in 13-HODE
production in HCT-116 cells is to be achieved.
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Figure 9. The effect of GT3 on the amount of 13-HODE secreted into the media of HCT-116 cells
analyzed by LC/MS/MS. HCT-116 cells were treated with and without 5 µM GT3 for 24 hours. The lipid
content was isolated from the media and analyzed by LC/MS/MS. The amount of 13-HODE in the media
was determined by stand curve analysis. The amount of 13-HODE in the media of HCT-116 cells treated
with GT3 demonstrated no statistical difference between the GT3 treated sample compared with the
vehicle treated sample (n =7; p = 0.37). Statistical differences were determined by paired t-test. p values
< 0.05 were determined to be statistically significant. p values are obtained at 95% confidence level.
Error bars are representative of SEM of sample.

GT, ATGT, AT or GT3 did not Regulate the Amount of 15-HETE in the Media of HCT116 Cells under Physiological Conditions.
15-HETE, a 15-LOX-1 metabolite, has been shown to be high in colorectal
cancer cells44. Higher levels of 15-HETE have been observed to enhance the growth
of colorectal cancer cells44,42. We, therefore, investigated whether vitamin E isoforms,
GT, GT3, AT, and ATGT can cause a reduction in the amount of 15-HETE in the media
of HCT-116 cells. The amount of 15-HETE in the media of HCT-116 cells did not show
a statistical difference after treatment with 5 µM GT under physiological conditions as
compared with the vehicle (Figure10; p = 0.36). Further, the amount of 15-HETE in the
media of HCT-116 cells following treatment with 5 µM ATGT under physiological
conditions did not show a statistical difference as compared with the vehicle (Figure 11;
p = 0.25). In addition, the amount of 15-HETE in the media of HCT-116 cells following
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treatment with 5 µM AT did not show a statistical difference after treatment as compared
with the vehicle (Figure 12; p = 0.49). Alongside GT (Figure 10), ATGT (Figure 11), and
AT (Figure 12), the amount of 15-HETE in the media of HCT-116 cells following
treatment with 5 µM GT3 did not show a statistical difference after treatment with 5 µM
GT3 as compared to the vehicle (Figure13; p = 0.47). These data demonstrate that the
production of 15-HETE under physiological conditions is not regulated by any of the
vitamin E isoforms tested (GT, AT, GT3) nor the ATGT mixture.

Figure 10. The effect of GT on the amount of 15-HETEsecreted into the media of HCT-116 cells as
analyzed by LC/MS/MS. HCT-116 cells were treated with and without 5 µM GT for 24 hours. The lipid
content was isolated from the media and analyzed by LC/MS/MS. The amount of 15-HETE in the media
was determined by stand curve analysis. The amount of 15-HETE in the media of HCT-116 cells treated
with GT demonstrated no statistical difference between the GT treated sample compared with the vehicle
treated sample (n =10; p = 0.36). Statistical differences were determined by paired t-test. p values < 0.05
were determined to be statistically significant. p values are obtained at 95% confidence level. Error bars
are representative of SEM of sample.
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Figure 11. The effect of ATGT on the amount of 15-HETE secreted into the media of HCT-116 cells as
analyzed by LC/MS/MS. HCT-116 cells were treated with and without 5 µM ATGT for 24 hours. The lipid
content was isolated from the media and analyzed by LC/MS/MS. The amount of 15-HETE in the media
was determined by stand curve analysis. The amount of 15-HETE in the media of HCT-116 cells treated
with ATGT demonstrated no statistical difference between the ATGT-treated sample compared with the
vehicle-treated sample (n = 8; p = 0.25). Statistical differences were determined by paired t-test. p values
< 0.05 were determined to be statistically significant. p values were obtained at 95% confidence level.
Error bars are representative of SEM of sample.

Figure 12. The effect of AT on the amount of 15-HETE secreted into the media of HCT-116 cells as
analyzed by LC/MS/MS. HCT-116 cells were treated with and without 5 µM AT for 24 hours. The lipid
content was isolated from the media and analyzed by LC/MS/MS. The amount of 15-HETE in the
media was determined by stand curve analysis. The amount of 15-HETE in the media of HCT-116 cells
treated with AT demonstrated no statistical difference between the AT-treated sample compared with
the vehicle-treated sample (n =8; p = 0.49). Statistical differences were determined by paired t-test. p
values < 0.05 were determined to be statistically significant. p values are obtained at 95% confidence
level. Error bars are representative of SEM of sample.
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Figure 13. The effect of GT3 on the amount of 15-HETE secreted into the media of HCT-116 cells as
analyzed by LC/MS/MS. HCT-116 cells were treated with and without 5 µM GT3 for 24 hours. The lipid
content was isolated from the media and analyzed by LC/MS/MS. The amount of 15-HETE in the media
was determined by stand curve analysis. The amount of 15-HETE in the media of HCT-116 cells treated
with GT3 demonstrated no statistical difference between the GT3-treated sample compared with the
vehicle-treated sample (n =8; p = 0.47). Statistical differences were determined by paired t-test. p values
< 0.05 were determined statistically significant. p values are obtained at 95% confidence level. Error bars
are representative of SEM of sample.

GT, but not GT3, AT, or ATGT Treatments Result in the Reduction of the 12-LOX
Metabolite, 12-HETE in HCT-116 Cells under Physiological Conditions.
12-HETE is produced through the metabolism of AA by the 12-LOX enzyme. 12HETE is found to play a role in the survival of cancer cells43,31. Higher levels of 12HETE is found to be present in the colorectal cancer cells compared to the normal
colorectal cells41,44. This high level of 12-HETE is shown to enhance cell proliferation in
cancer cells including colorectal and prostate cancers44,41,16,46. Reduction in the level of
12-HETE by its inhibitors (i.e. flavonoid, baicalein, and cinnamyl-3, 4-dihydroxy-acyanocinnamide), decreased cell proliferation in cancer cells43,31. We have, therefore,
investigated whether the amount of 12-HETE secreted into the media of HCT-116 cells
can be reduced by treatment with vitamin E isoforms GT, GT3, AT, and ATGT.
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The amount of 12-HETE secreted into the media under physiological conditions
was significantly decreased following treatment of HCT-116 cells with 5 µM GT as
compared to the vehicle (Figure 14; p = 0.0014). However, the amount of 12-HETE
secreted into the media of HCT-116 cells after treatment of the cells with 5 µM ATGT
under physiological conditions did not show a statistical difference as compared with the
vehicle (Figure 15; p = 0.30). In addition, the amount of 12-HETE secreted into the
media following treatment of HCT-116 cells with 5 µM AT under physiological conditions
did not show statistical difference compared with the vehicle (Figure 16; p = 0.45).
Treatment of HCT-116 cells with GT3 did not show a statistical significance difference in
the amount of 12-HETE secreted into the media compared with the vehicle (Figure 17; p
= 0.29). These data show that the amount of 12-HETE produced into the media of
HCT-116 is reduced only by GT treatment.

Figure 14. The effect of GT on the amount of 12-HETE secreted into the media of HCT-116 cells as
analyzed by LC/MS/MS. HCT-116 cells were treated with and without 5 µM GT for 24 hours. The lipid
content was isolated from the media and analyzed by LC/MS/MS. The amount of 12-HETE in the media
was determined by stand curve analysis. The amount of 12-HETE in the media of HCT-116 cells treated
with GT demonstrates a significant decrease over the vehicle-treated cells (n =7; p = 0.0014). Statistical
differences were determined by paired t-test. p values < 0.05 were determined to be statistically
significant. p values were obtained at 95% confidence level. Error bars are representative of SEM of
sample.
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Figure 15. The effect of ATGT on the amount of 12-HETE secreted into the media of HCT-116 cells as
analyzed by LC/MS/MS. HCT-116 cells were treated with and without 5 µM ATGT for 24 hours. The lipid
content was isolated from the media and analyzed by LC/MS/MS. The amount of 12-HETE in the media
was determined by stand curve analysis. The amount of 12-HETE in the media of HCT-116 cells treated
with ATGT demonstrated no statistical difference between the ATGT treated sample compared with the
vehicle treated sample (n =7; p = 0.30). Statistical differences were determined by paired t-test. p values
< 0.05 were determined to be statistically significant. p values were obtained at 95% confidence level.
Error bars are representative of SEM of sample.

Figure 16. The effect of AT on the amount of 12-HETE secreted into the media of HCT-116 cells as
analyzed by LC/MS/MS. HCT-116 cells were treated with and without 5 µM AT for 24 hours. The lipid
content was isolated from the media and analyzed by LC/MS/MS. The amount of 12-HETE in the media
was determined by stand curve analysis. The amount of 12-HETE in the media of HCT-116 cells treated
with AT demonstrated no statistical difference between the AT treated sample compared with the vehicle
treated sample (n =8; p = 0.45). Statistical differences were determined by paired t-test. p values < 0.05
were determined to be statistically significant. p values were obtained at 95% confidence level. Error
bars are representative of SEM of sample.
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Figure 17. The effect of GT3 on the amount of 12-HETE secreted into the media of HCT-116 cells
analyzed by LC/MS/MS. HCT-116 cells were treated with and without 5 µM GT3 for 24 hours. The lipid
content was isolated from the media and analyzed by LC/MS/MS. The amount of 12-HETE in the media
was determined by stand curve analysis. The amount of 12-HETE in the media of HCT-116 cells treated
with GT3 demonstrated no statistical difference between the GT3 treated sample compared with the
vehicle treated sample (n =8; p = 0.29). Statistical differences were determined by paired t-test. p values
< 0.05 were determined to be statistically significant. p values were obtained at 95% confidence level.
Error bars are representative of SEM of sample.

The Amount of 5-HETE Secreted into the Media of HCT-116 Cells was not Affected by
GT, AT, ATGT, or GT3 under Physiological Conditions.
5-LOX, the enzyme which metabolizes AA to produce 5-HETE has been shown
to be highly expressed in colorectal cancer cells47. High levels of 5-LOX enzyme in
colorectal cancer cells is linked to increased tumor size and growth48. Addition of 5LOX inhibitors to colorectal cancer cells decreases cell proliferation47. We therefore
chose to investigate whether the addition of vitamin E isoforms, GT, AT, GT3, and
ATGT mixture can decrease the amount of 5-HETE (5-LOX metabolite) secreted into
the media of HCT-116 cells.
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The amount of 5-HETE secreted into the media did not show any significant
change after treatment of HCT-116 cells under physiological conditions with 5 µM GT as
compare with the vehicle (Figure 18; p = 0.49). Further, the amount of 5-HETE
secreted into the media following treatment of HCT-116 cells with 5 µM ATGT under
physiological conditions did not show a statistically significant difference compared with
the vehicle (Figure 19; p = 0.24). Neither did the amount of 5-HETE secreted into the
media following treatment of HCT-116 cells under physiological conditions with 5 µM AT
show a statistically significant difference as compared with the vehicle Figure 20; p =
0.072. The amount of 5-HETE in the media following treatment of HCT-116 cells under
physiological conditions with 5 µM GT3 did not show a significance difference as
compared with the vehicle (Figure 21; p = 0.24). These data suggest that treatment of
HCT-116 cells with vitamin E isoforms GT, AT, ATGT mixture as well as GT3, did not
reduce the amount of 5-HETE secreted into the media.

Figure 18. The effect of GT on the amount of 5-HETE secreted into the media of HCT-116 cells as
analyzed by LC/MS/MS. HCT-116 cells were treated with and without 5 µM GT for 24 hours. The lipid
content was isolated from the media and analyzed by LC/MS/MS. The amount of 5-HETE in the media
was determined by stand curve analysis. The amount of 5-HETE in the media of HCT-116 cells treated
with GT demonstrated no statistical difference between the GT-treated sample compared with the
vehicle-treated (n =11; p = 0.49). Statistical differences were determined by paired t-test. p values < 0.05
were determined to be statistically significant. p values were obtained at 95% confidence level. Error bars
are representative of SEM of sample.

52

Figure 19. The effect of ATGT on the amount of 5-HETE secreted into the media of HCT-116 cells
analyzed by LC/MS/MS. HCT-116 cells were treated with and without 5 µM ATGT for 24 hours. The lipid
content was isolated from the media and analyzed by LC/MS/MS. The amount of 5-HETE in the media
was determined by stand curve analysis. The amount of 5-HETE in the media of HCT-116 cells treated
with ATGT demonstrated no statistical difference between the ATGT treated sample compared with the
vehicle treated sample (n =9; p = 0.24). Statistical differences were determined by paired t-test. p values
< 0.05 were determined to be statistically significant. p values were obtained at 95% confidence level.
Error bars are representative of SEM of sample.

Figure 20. The effect of AT on the amount of 5-HETE secreted into the media of HCT-116 cells as
analyzed by LC/MS/MS. HCT-116 cells were treated with and without 5 µM AT for 24 hours. The lipid
content was isolated from the media and analyzed by LC/MS/MS. The amount of 5-HETE in the media
was determined by stand curve analysis. The amount of 5-HETE in the media of HCT-116 cells treated
with AT demonstrated no statistical difference between the AT treated sample compared with the vehicle
treated sample (n =8; p = 0.072). Statistical differences were determined by paired t-test. p values < 0.05
were determined to be statistically significant. p values were obtained at 95% confidence level. Error
bars are representative of SEM of sample.
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Figure 21. The effect of GT3 on the amount of 5-HETE secreted into the media of HCT-116 cells
analyzed by LC/MS/MS. HCT-116 cells were treated with and without 5 µM GT3 for 24 hours. The lipid
extract was isolated from the media and analyzed by LC/MS/MS. The amount of 5-HETE in the media
was determined by stand curve analysis. The amount of 5-HETE in the media of HCT-116 cells treated
with GT3 demonstrated no statistical difference between the GT3 treated sample compared with the
vehicle treated sample (n =9; p = 0.24). Statistical differences were determined by paired t-test. p values
< 0.05 were determined to be statistically significant. p values were obtained at 95% confidence level.
Error bars are representative of SEM of sample.

The Amount of 13-HODE, 15-HETE, 12-HETE, and 5-HETE Produced in HCT-116
Cells Following Treatment with GT, AT, ATGT, or GT3 and then Activation of the
Lipoxygenase Pathway with Calcium Ionophore A23187 and Addition of Arachidonic
Acid.
The amount of polyunsaturated fatty acid metabolites, 13-HODE, 15-HETE, 12HETE, and 5-HETE were also measured in HCT-116 cells following treatment of HCT116 cells with vitamin E isoforms, GT, AT, ATGT, and AT and activation of the LOX
pathway with the calcium ionophore A23187 and addition of exogenous AA. If the
corresponding LOX enzyme was still active after the treatment under physiological
conditions, the exogenous AA that was added to the cells provides enough substrate to
be used by the LOX enzymes for the production of 5-HETE, 15-HETE, and 12-HETE in
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HCT-116 cells. If the enzyme is inactivated following the secretion of the metabolites
into the media, additional HETE metabolites will not be produced by the cells.
Under LOX Activation Conditions, GT3, but not GT, ATGT, or AT Reduce the
Production of 13-HODE in HCT-116 Cells.
To obtain a concentration range of 13-HODE in the cells for standard preparation
and to ensure that the extraction method was valid, the amount of 13-HODE in HCT116 cells was initially measured using ELISA method. This was carried out by
preparing 13-HODE standards and a calibration graph. Using the ELISA method,
amount of 13-HODE in HCT-116 cells following treatment with 5 µM GT after 24 hours
did not show a statistically significant difference as compared to the vehicle (Figure 22;
p = 0.096). Using LC/MS/MS, the amount of 13-HODE produced in HCT-116 cells
following treatment with 5 µM GT did not show statistical difference as compared with
the vehicle (Figure 23; p = 0.39).

Figure 22. The effect of GT on the amount of 13-HODE in HCT-116 cells using the ELISA method.
HCT-116 cells were treated with 5 M GT for 24 hours. The lipid content was isolated from HCT-116
cells following treatment with GT. Activation of cells with the calcium ionophore A23187 and addition of
exogenous AA was carried out and the lipids were analyzed by the ELISA method. The amount of 13HODE was determined by stand curve analysis. The amount of 13-HODE in HCT-116 cells shows no
statistical difference between the vehicle-treated and the GT-treated sample (n=7; p = 0.096). Statistical
differences were determined by paired t-test. p values < 0.05 were determined statistically significant.
Error bars are representative of SEM of sample
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Figure 23. The effect of GT on the amount of 13-HODE in HCT-116 cells as analyzed by LC/MS/MS.
HCT-116 cells were treated with and without 5 µM GT for 24 hours. The lipid content was isolated from
HCT-116 cells following treatment with GT. Activation of cells with the calcium ionophore A23187 and
addition of exogenous AA was carried out and the lipids were analyzed by LC/MS/MS. The amount of
13-HODE in HCT-116 cells was determined by stand curve analysis. The amount of 13-HODE in HCT116 cells treated with GT demonstrated no statistical difference between the GT- treated sample
compared with the vehicle-treated sample (n =11; p = 0.39). Statistical differences were determined by
paired t-test. p values < 0.05 were determined statistically significant. p values were obtained at 95%
confidence level. Error bars are representative of SEM of sample.

Treatment of HCT-116 cells with 5 µM ATGT and 5 µM AT did not show
statistical differences as compared with the vehicle (Figures 24 and 25) with p values of
0.14 and 0.16, respectively. These data suggest that, after secretion of 13-HODE into
the media, there is less substrate (linoleic acid) for the 15-LOX-1 to act upon or the 15LOX-1 enzyme has been inactivated following the treatment with GT or ATGT (Figures
23, 24, and 25).
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Figure 24. The effect of ATGT on the amount of 13-HODE of HCT-116 cells as analyzed by LC/MS/MS.
HCT-116 cells were treated with and without 5 µM ATGT for 24 hours. The lipid content was isolated
from the HCT-116 cells following treatment with ATGT. Activation of cells with the calcium ionophore
A23187 and the addition of exogenous AA were carried out, and the lipids were analyzed by LC/MS/MS.
The amount of 13-HODE in the HCT-116 cells was determined by stand curve analysis. The amount of
13-HODE in HCT-116 cells shows no statistical difference between the ATGT-treated sample and the
vehicle-treated sample treated sample (n =9; p = 0.14). Statistical differences were determined by paired
t-test. p values < 0.05 were determined statistically significant. p values are obtained at 95% confidence
level. Error bars are representative of SEM of sample.

Figure 25. The effect of AT on the amount of 13-HODE of HCT-116 cells as analyzed by LC/MS/MS.
HCT-116 cells were treated with and without 5 µM AT for 24 hours. The lipid content was isolated from
the HCT-116 cells following treatment with AT. Activation of cells with the calcium ionophore A23187 and
the addition of exogenous AA were carried out, and the lipids were analyzed by LC/MS/MS. The amount
of 13-HODE in the HCT-116 cells was determined by stand curve analysis. The amount of 13-HODE in
HCT-116 cells shows no statistical difference between the AT-treated sample and the vehicle-treated
sample (n =8; p = 0.16). Statistical differences were determined by paired t-test. p values < 0.05 were
determined statistically significant. p values are obtained at 95% confidence level. Error bars are
representative of SEM of sample.
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While the treatment of the tocopherols showed no significant increase in 13HODE production, treatment of HCT-116 cells with GT3 significantly decreased the
production of 13-HODE as compared with the vehicle (Figure 26; p = 0.0092). This
decrease is likely due to the decrease in the limited substrate availability (linoleic acid),
if GT3 were decreasing the activity of the 15-LOX-1 enzyme there would be a significant
decrease in the production of 15-HETE in the presence of GT3, but that does not
happen (Figure 31). The decrease in the amount of 13-HODE in HCT-116 cells after
treatment with 5 µM GT3 was also observed during the preliminary analysis with ELISA
method (Figure 27).

Figure 26. The effect of GT3 on the amount of 13-HODE of HCT-116 cells as analyzed by LC/MS/MS.
HCT-116 cells were treated with and without 5 µM GT3 for 24 hours. The lipid content was isolated from
the HCT-116 cells following treatment with GT3. Activation of the cells with the calcium ionophore A23187
and the addition of exogenous AA was carried out, and the lipids were analyzed by LC/MS/MS. The
amount of 13-HODE in the HCT-116 cells was determined by stand curve analysis. The amount of 13HODE in HCT-116 cells show a statistically significant decrease in the GT3-treated sample compared
with the vehicle (n=7; p = 0.0092). Statistical differences were determined by paired t-test. p values <
0.05 were determined statistically significant. p values were obtained at 95% confidence level. Error bars
are representative of SEM of sample.
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Figure 27. The effect of GT3 on the amount of 13-HODE in HCT-116 cells as analyzed by the ELISA
method. HCT-116 cells were treated with and without 5 M GT3 for 24 hours. The lipid content was
isolated from the HCT-116 cells following treatment with GT3. Activation of the cells with the calcium
ionophore A23187 and the addition of exogenous AA was carried out, and the lipids were analyzed by the
ELISA method. The amount of 13-HODE in the HCT-116 cells was determined by stand curve analysis.
The amount of 13-HODE in HCT-116 cells show a statistically significant decrease in the GT3-treated
sample compared with the vehicle (n=7; p = 0.015). Statistical differences were determined by paired ttest. p values < 0.05 were determined statistically significant. Error bars are representative of SEM of
sample.

GT, ATGT, AT, nor GT3 Regulate the Production of 15-HETE in HCT-116 Cells.
The amount of 15-HETE produced in HCT-116 cells following treatment with 5
µM GT shows no significant difference as compared with the vehicle (Figure 28; p =
0.081). In addition, the production of 15-HETE following treatment with 5 µM ATGT
shows no significant difference as with the vehicle (Figure 29; p = 0.39). Further,
treatment of HCT-116 cells with 5 µM AT and 5 µM GT3 shows no statistical difference
in the amount of 15-HETE as compared with the vehicle (Figures 30 and 31) with p
values of 0.12 and 0.21, respectively. These data indicate that neither GT, ATGT, AT,
nor GT3 significantly regulate the production of 15-HETE in HCT-116 cells after
activation of the LOX pathway with the calcium ionophore A23187 and addition of
exogenous AA to the cells.
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Figure 28. The effect of GT on the amount of 15-HETE in HCT-116 cells as analyzed by LC/MS/MS.
HCT-116 cells were treated with and without 5 µM GT for 24 hours. The lipid content was isolated from
the HCT-116 cells following treatment with GT. Activation of cells with the calcium ionophore A23187 and
the addition of exogenous AA were carried out, and the lipids were analyzed by LC/MS/MS. The amount
of 15-HETE in the HCT-116 cells was determined by stand curve analysis. The amount of 15-HETE in
HCT-116 cells shows no statistical difference between the GT-treated sample and the vehicle-treated
sample (n =10; p = 0.081). Statistical differences were determined by paired t-test. p values < 0.05 were
determined statistically significant. p values were obtained at 95% confidence level. Error bars are
representative of SEM of sample.

Figure 29. The effect of ATGT on the amount of 15-HETE in HCT-116 cells as analyzed by LC/MS/MS.
HCT-116 cells were treated with and without 5 µM ATGT for 24 hours. The lipid content was isolated
from HCT-116 cells following treatment with ATGT Activation of cells with the calcium ionophore A23187
and the addition of exogenous AA was carried out, and the lipids were analyzed by LC/MS/MS. The
amount of 15-HETE in the HCT-116 cells was determined by stand curve analysis. The amount of 15HETE in HCT-116 cells shows no statistical difference between the ATGT-treated sample and the
vehicle-treated sample treated (n =8; p = 0.39). Statistical differences were determined by paired t-test. p
values < 0.05 were determined statistically significant. p values are obtained at 95% confidence level.
Error bars are representative of SEM of sample.
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Figure 30. The effect of AT on the amount of 15-HETE of HCT-116 cells as analyzed by LC/MS/MS.
HCT-116 cells were treated with and without 5 µM AT for 24 hours. The lipid content was isolated from
the HCT-116 cells following treatment with AT. Activation of cells with the calcium ionophore A23187 and
the addition of exogenous AA were carried out, and the lipids were analyzed by LC/MS/MS. The amount
of 15-HETE in HCT-116 cells was determined by stand curve analysis. The amount of 15-HETE in HCT116 cells shows no statistical difference between the AT-treated sample and the vehicle-treated sample
(n =8; p = 0.12). Statistical differences were determined by paired t-test. p values < 0.05 were
determined statistically significant. p values are obtained at 95% confidence level. Error bars are
representative of SEM of sample.

Figure 31. The effect of GT3 on the amount of 15-HETE of HCT-116 cells as analyzed by LC/MS/MS.
HCT-116 cells were treated with and without 5 µM GT3 for 24 hours. The lipid content was isolated from
the HCT-116 cells following treatment with GT3. Activation of cells with the calcium ionophore A23187
and the addition of exogenous AA were carried out, and the lipids were analyzed by LC/MS/MS. The
amount of 15-HETE in CT-116 cells was determined by stand curve analysis. The amount of 15-HETE in
HCT-116 cells shows no statistical difference between the GT3-treated sample and the vehicle-treated (n
=8; p = 0.21). Statistical differences were determined by paired t-test. p values < 0.05 were determined
statistically significant. p values are obtained at 95% confidence level. Error bars are representative of
SEM of sample.
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ATGT or GT3 Decrease the Production of 12-HETE in HCT-116 Cells after LOX
Activation while AT Increases the Production but GT Does not Change the Production
of 12-HETE.

The amount of 12-HETE produced in HCT-116 cells after treatment with GT, AT,
ATGT, and GT3 followed by activation of calcium ionophore and addition of exogenous
AA was measured. The production of 12-HETE in HCT-116 cells after treatment with 5
µM GT did not show a statistical difference as compared with the vehicle (Figure 32; p =
0.47). Interestingly, treatment of HCT-116 cells with 5 µM ATGT significantly decreases
the production of 12-HETE in HCT-116 cells as compared with the vehicle (Figure 33; p
= 0.024). However, treatment of the cells with 5 µM AT significantly increased the
production of 12-HETE in HCT-116 cells as compared with the vehicle (Figure 34; p =
0.034). In addition, treatment of the HCT-116 cells with 5 µM GT3 significantly
decreased the production of 12-HETE as compared with the vehicle (Figure 35; p =
0.027). These data indicate that the activity of the 12-LOX is decreased by ATGT
mixture and GT3 treatments.
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Figure 32. The effect of GT on the amount of 12-HETE in HCT-116 cells as analyzed by LC/MS/MS.
HCT-116 cells were treated with and without 5 µM GT for 24 hours. The lipid content was isolated from
the HCT-116 cells following treatment with GT. Activation of cells with the calcium ionophore A23187 and
the addition of exogenous AA was carried out. The lipids were analyzed by LC/MS/MS. The amount of
12-HETE in the HCT-116 cells was determined by stand curve analysis. The amount of 12-HETE in HCT116 cells treated shows no statistical difference between the GT-treated sample and the vehicle-treated
sample (n =10; p = 0.47). Statistical differences were determined by paired t-test. p values < 0.05 were
determined statistically significant. p values are obtained at 95% confidence level. Error bars are
representative of SEM of sample.

Figure 33. The effect of ATGT on the amount of 12-HETE in HCT-116 cells as analyzed by LC/MS/MS.
HCT-116 cells were treated with and without 5 µM ATGT for 24 hours. The lipid content was isolated
from the HCT-116 cells following treatment with ATGT. Activation of cells with the calcium ionophore
A23187 and the addition of exogenous AA were carried out. The lipids were analyzed by LC/MS/MS.
The amount of 12-HETE in the HCT-116 cells was determined by stand curve analysis. The amount of
12-HETE in HCT-116 cells show a statistically significant decrease in the ATGT-treated sample compared
with the vehicle treated sample (n =8; p = 0.024). Statistical differences were determined by paired t-test.
p values < 0.05 were determined statistically significant. p values are obtained at 95% confidence level.
Error bars are representative of SEM of sample.
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Figure 34. The effect of AT on the amount of 12-HETE of HCT-116 cells as analyzed by LC/MS/MS.
HCT-116 cells were treated with and without 5 µM AT for 24 hours. The lipid content was isolated from
the HCT-116 cells following treatment with AT. Activation of cells with the calcium ionophore A23187 and
the addition of exogenous AA were carried out. The lipids were analyzed by LC/MS/MS. The amount of
12-HETE in the HCT-116 cells was determined by stand curve analysis. The amount of 12-HETE in HCT116 cells show a statistically significant increase in the AT-treated sample compared with the vehicle
treated sample (n =7; p = 0.034). Statistical differences were determined by paired t-test. p values < 0.05
were determined statistically significant. p values are obtained at 95% confidence level. Error bars are
representative of SEM of sample.

Figure 35. The effect of GT3 on the amount of 12-HETE in HCT-116 cells as analyzed by LC/MS/MS.
HCT-116 cells were treated with and without 5 µM GT3 for 24 hours. The lipid content was isolated from
the HCT-116 cells following treatment with GT3. Activation of cells with the calcium ionophore A23187
and the addition of exogenous AA was carried out, and the lipids were analyzed by LC/MS/MS. The
amount of 12-HETE in the HCT-116 cells was determined by stand curve analysis. The amount of 12HETE in HCT-116 cells show a statistically significant decrease in the GT3-treated sample compared with
the vehicle (n =8; p = 0.027). Statistical differences were determined by paired t-test. p values < 0.05
were determined statistically significant. p values are obtained at 95% confidence level. Error bars are
representative of SEM of sample.
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5-HETE is Decreased by GT3, Increased by AT and not Changed by GT or ATGT
Treatments after Activation of LOX Pathway by the Calcium Ionophore (A23187) and
Arachidonic Acid.

The amount of 5-HETE produced in HCT-116 cell following treatments with
vitamin E isoforms, GT, AT, GT3, and ATGT mixture and further activation of the cells
with calcium ionophore and addition of AA was also investigated. 5-HETE in HCT-116
cells is not significantly decreased by treatment with 5 µM GT as compared with the
vehicle (Figure 36; p = 0.11). Treatment of HCT-116 cells with 5 µM ATGT did not
significantly decrease the production of 5-HETE in HCT-116 cells as compared with the
vehicle (Figure 37; p = 0.11). However, treatment of HCT-116 cells with 5 µM AT
significantly increased the production of 12-HETE as compared with the vehicle (Figure
38; p = 0.037). In addition, 5 µM GT3 significantly decreased the production of 5-HETE
in HCT-116 cells (Figure 39; p = 0.046). These data indicate that only GT3 allowed for
a significant decrease in the production of 5-HETE production after activation of HCT116 cells with the calcium ionophore and the addition of exogenous AA. The increase
in the production of 5-HETE by AT after activation of HCT-116 cells with calcium
ionophore and addition AA suggest that the 5-LOX enzyme is still active allowing for the
production of 5-HETE.
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Figure 36. The effect of GT on the amount of 5-HETE of HCT-116 cells as analyzed by LC/MS/MS.
HCT-116 cells were treated with and without 5 µM GT for 24 hours. The lipid content was isolated from
the HCT-116 cells following treatment with GT. Activation with calcium ionophore and the addition of
exogenous AA were carried out. The lipids were analyzed by LC/MS/MS. The amount of 5-HETE in the
HCT-116 cells was determined by stand curve analysis. The amount of 5-HETE in HCT-116 cells shows
no statistical difference between the GT-treated sample and the vehicle-treated sample (n =11; p = 0.11).
Statistical differences were determined by paired t-test. p values < 0.05 were determined statistically
significant. p values are obtained at 95% confidence level. Error bars are representative of SEM of
sample.

Figure 37. The effect of ATGT on the amount of 5-HETE of HCT-116 cells as analyzed by LC/MS/MS.
HCT-116 cells were treated with and without 5 µM ATGT for 24 hours. The lipid content was isolated
from the HCT-116 cells following treatment with ATGT. Activation with calcium ionophore and the
addition of exogenous AA were carried out. The lipids were analyzed by LC/MS/MS. The amount of 5HETE in the HCT-116 cells was determined by stand curve analysis. The amount of 5-HETE in HCT-116
cells shows no statistical difference between the ATGT-treated sample and the vehicle-treated sample
(n= 9; p = 0.11). Statistical differences were determined by paired t-test. p values < 0.05 were
determined statistically significant. p values are obtained at 95% confidence level. Error bars are
representative of SEM of sample.
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Figure 38. The effect of AT on the amount of 5-HETE in HCT-116 cells as analyzed by LC/MS/MS. HCT116 cells were treated with and without 5 µM AT for 24 hours. The lipid content was isolated from the
HCT-116 cells following treatment with AT. Activation of cells with the calcium ionophore A23187 and the
addition of exogenous AA was carried out, and the lipids were analyzed by LC/MS/MS. The amount of 5HETE in the HCT-116 cells was determined by stand curve analysis. The amount of 5-HETE in HCT-116
cells shows a statistically significant increase in the AT-treated sample compared with the vehicle (n =8; p
= 0.037). Statistical differences were determined by paired t-test. p values < 0.05 were determined
statistically significant. p values are obtained at 95% confidence level. Error bars are representative of
SEM of sample.

Figure 39. The effect of GT3 on the amount of 5-HETE in HCT-116 cells as analyzed by LC/MS/MS.
HCT-116 cells were treated with and without 5 µM GT3 for 24 hours. The lipid content was isolated from
the HCT-116 cells following treatment with GT3. Activation of cells with the calcium ionophore A23187
and the addition of exogenous AA was carried out, and the lipids were analyzed by LC/MS/MS. The
amount of 5-HETE in the HCT-116 cells was determined by stand curve analysis. The amount of 5-HETE
in HCT-116 cells shows a statistically significant decrease in the GT3-treated sample compared with the
vehicle (n =7; p = 0.046). Statistical differences were determined by paired t-test. p values < 0.05 were
determined statistically significant. p values are obtained at 95% confidence level. Error bars are
representative of SEM of sample.
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CHAPTER 4
DISCUSSION
In this study we found that, under both, physiological conditions and LOX
induction by calcium ionophore A23187, each isoform of vitamin E tested (GT, AT, GT3
and ATGT mixture) exhibited different effects on the production of polyunsaturated fatty
acid metabolites (LOX metabolites). Since these metabolites (13-HODE, 15-HETE,12HETE, and 5-HETE) have previously been associated with colorectal cancer
development52,44,67, we were interested in determining whether vitamin E isoforms have
the ability to regulate the LOX pathway through the production of the LOX metabolites.
Under normal physiological conditions, we discovered that GT increases the
amount of 13-HODE (Figure 6), and decreases the amount of 12-HETE in the media of
HCT-116 cells (Figure 14), but does not regulate the amount of 15-HETE or 5-HETE in
the media of HCT-116 cells (Figures 10 and 18).
NSAIDs like sulindac and NS398 enhance 13-HODE production in colorectal
cancer cells53,54. GT mirrors this function of NSAIDs in colorectal cancer cells. The
flavonoid baicalein and sulindac are 12-LOX inhibitors and thereby inhibiting the
production of 12-HETE in colorectal cancer cells42,41. GT also mirrors the function of
12-LOX inhibitors under physiological conditions as it down regulates the production of
12-HETE into the media of HCT-116 cells treated under physiological conditions (Figure
14).
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We found that under physiological conditions, the ATGT mixture (95% GT and
5% AT) increases the production of 13-HODE secreted into the media from HCT-116
cells (Figure 7). However, the ATGT mixture does not regulate the amount of 15-HETE
(Figure 11), 12-HETE (Figure 15), or 5-HETE (Figure 19) produced and secreted in the
media of HCT-116 cells.
This study demonstrates that, under normal physiological conditions, AT
decreases the ability of GT to regulate the production of 13-HODE and 12-HETE
secreted into the HCT-116 media. This is evidenced by the fact that the ATGT mixture
demonstrated less than a 2 fold increase in 13-HODE compared to the vehicle (Figure
7) while pure GT demonstrated a 5 fold increase in 13-HODE compared to the vehicle
(Figure 6). Further, the ATGT mixture (Figure 15) did not significantly decrease the
amount of 12-HETE secreted in the HCT-116 media as did pure GT (Figure 14). Pure
AT did not significantly regulate the production of 13-HODE (Figure 8) or 12-HETE
(Figure 16) under physiological conditions. In fact, AT under physiological conditions
had no effect on any of the metabolites (13-HODE (Figure 8), 12-HETE (Figure 16), 5HETE (Figure 12) or 5-HETE (Figure 20).
Our study shows that, under normal physiological conditions, GT3 does not
significantly affect the amount of 13-HODE (Figure 9), 15-HETE (Figure 13), 12-HETE
(Figure 17), and 5-HETE (Figure 21) secreted in the media of the HCT-116 cells.
Hence, under normal physiological conditions, GT shows a greater effect in
regulating the production of polyunsaturated fatty acid metabolites as it increases the

69

amount of 13-HODE and decreases the amount of 12-HETE secreted in the media of
the HCT-116 cells.
When examining the production of the metabolites under the LOX activation
conditions (addition of the calcium ionophore A23187 with exogenous AA to the cells
post treatment), we observed that the 12-LOX enzyme was no longer active. The
production of 12-HETE (Figure 32) in the cells as compared with the vehicle were not
significantly increased. A possible reason for the reduction may be a lack of substrate
availability or enzyme activity. We would expect that if the 12-LOX enzyme was still
active, the amount of 12-HETE produced after activation of cells with calcium ionophore
A23187 and addition of AA should increase following treatment with GT. However, the
amount of 12-HETE produced in the GT-treated samples did not significantly change as
compared with the vehicle under conditions that would activate the LOX pathway, which
suggests that the 12-LOX activity is reduced by the GT pretreatment. The decrease in
activity of the 12-LOX enzyme by GT was also observed as the amount of 12-HETE
produced and secreted in the media under physiological conditions was significantly
lower when compared with the vehicle (Figure 14).
As previously observed in the media (Figure 11 and 19), ATGT did not
significantly decrease the amount of 15-HETE (Figure 29) and 5-HETE (Figure 37) in
HCT-116 cells under LOX Activation conditions, thus confirming that ATGT does not
significantly regulate the amount of 15-HETE or 5-HETE in HCT-116 cells neither under
physiological conditions nor with LOX activation by the calcium ionophore A23187 and
additional AA.
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In addition, AT was observed to significantly increase the production of 12-HETE
(Figure 34) and 5-HETE (Figure 38) after addition of calcium ionophore A23187 and
exogenous AA to the cells, although under normal physiological conditions AT did not
significantly increase the amount of 12-HETE or 5-HETE produced into the media
(Figures 16 and 20). It is possible that under normal physiological conditions, there is
not enough substrate (AA) present in the cells to be metabolized by 12-LOX or 5-LOX
enzyme after treatment with AT. It is also possible that the addition of calcium
ionophore A23187 activated the LOX pathway enhancing the activity of the 12-LOX or
5-LOX enzyme and allowing AT to produce more 12-HETE or 5-HETE in the cells.
Further, we observed that GT3 has no effect on LOX metabolism under
physiological conditions, but significantly decreases the production of 13-HODE
(Figures 26 and 27), 12-HETE (Figure 35), and 5-HETE (Figure 39) conditions of LOX
activation. Thus, it is possible that the activity of 15-LOX-1, 12-LOX, and 5-LOX in
HCT-116 cells are reduced by GT3 treatment. The addition of AA to the cells will
provide the substrate necessary to produce the 12-HETE and 5-HETE. It is also
possible that GT3 prevents the activation of the LOXs on AA. Additional studies are
necessary to determine the role that GT3 plays on the statistically significant inhibition
of 12-HETE and 5-HETE production following the activation of the LOX pathway with
the calcium ionophore A23187 and AA.
Finally, we found that none of the vitamin E isoforms tested (GT, AT, ATGT and
GT3) significantly regulates the production of 15-HETE in HCT-116 cells either under
normal physiological conditions or LOX activation conditions.
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In summary:
Table 1. Amount of 13-HODE, 15-HETE, 12-HETE, and 5-HETE Secreted into the
Media of HCT-116 Cells after Treatment of Cells with 5 µM GT, AT, ATGT, or GT3
under Physiological Conditions.
Vitamin E
isoforms

13-HODE

15-HETE

12-HETE

5-HETE

GT

Increase

Not statistically
significant

Decrease

Not
statistically
significant

ATGT

Increase

Not statistically
significant

Not statistically
significant

Not
statistically
significant

AT

Not statistically
significant

Not statistically
significant

Not statistically
significant

Not
statistically
significant

GT3

Not statistically
significant

Not statistically
significant

Not statistically
significant

Not
statistically
significant
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Table 2. Production of 13-HODE, 15-HETE, 12-HETE, and 5-HETE Following 24 hour
Pretreatment of HCT-116 Cells with 5 µM GT, AT, ATGT, or GT3 and Subsequent LOX
Activation with the Addition of Calcium Ionophore A23817and Exogenous Arachidonic
Acid.
Vitamin E
isoforms

13-HODE

15-HETE

12-HETE

5-HETE

GT

Not statistically
significant

Not statistically
significant

Not statistically
significant

Not statistically
significant

ATGT

Not statistically
significant

Not statistically
significant

Decrease

Not statistically
significant

AT

Not statistically
significant

Not statistically
significant

Increase

Increase

GT3

Decrease

Not statistically
significant

Decrease

Decrease

In conclusion, the vitamin E isoforms, GT, GT3, AT as well as ATGT mixture did
not have the same effect on the production of polyunsaturated fatty acid, 13-HODE, 15HETE, 12-HETE, and 5-HETE under physiological conditions or LOX activation
conditions. Under normal physiological conditions, GT is the best isoform of vitamin E
as it increases the amount of 13-HODE and decreases 12-HETE in media of HCT-116
cells. It was also determined that under normal physiological conditions, AT has the
ability to decrease the activity of GT in regulating the production of 13-HODE and 12HETE in the media of HCT-116 cells.
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Analytical Problems and Future Directions
Problems. Random error was observed in the data collected during this project.
Hence, high number of replicates was done to enhance the precision of the data. A
paired t-test was used to examine whether the metabolites obtained from the vehicle
and treated samples are statistically significant.
Analytes obtained from extract initially precipitated at higher pH values (5.5-7.4)
when dissolved in the following solvent system: ethanol, methanol, hexane, and
ammonium acetate. The pH of the solution was therefore decreased to about 3.5-4.0
which prevented precipitation of the analyte in the solvent (methanol) used for
dissolving these analytes. This is because the analytes obtained after extraction are
fatty acids and exhibit high solubility as the pH of the solution is decreased.
Future Work. We would like to investigate the concentrations of HETEs (12HETE, 15-HETE, and 5-HETE) and 13-HODE when LA is added during the isolation
rather than AA. This experiment would be aimed at determining if reduction of 13HODE production observed with GT and ATGT in the cells is due to lack of substrate or
reduced enzyme activity.
We would also like to investigate the concentrations of HETEs (12-HETE, 15HETE, and 5-HETE) and 13-HODE in the presence of chemical inhibitors for 15-LOX
(e.g. 6, 11-dihydro-[1]benzothiopyrano[4,3-b]indole(PD146176)), 12-LOX (e.g. caffeic
acid), and 5-LOX (e.g. AA861). These experiments would enable us to know the
predominant LOX pathway that causes cell death in colorectal cancer cells.
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APPENDICES
Appendix A
Tables of Confidence Limits and p-values
Table 3. Confidence Intervals (CI) for 13-HODE, 15-HETE, 12-HETE, and 5-HETE in
the Media of HCT-116 Cells Obtained at 95% Confidence Level
Vitamin E
isoforms

13-HODE

15-HETE

12-HETE

5-HETE

GT

Figure 6

Figure 10

Figure 14

Figure 18

CI = - 5.5 to
0.40

CI = - 0.37 to
0.27

CI = 0.23 to 0.69

CI = -1.0 to
1.0

Figure 7

Figure 11

Figure 15

Figure 19

CI = - 1.4 to
0.13

CI = - 0.60 to
1.17

CI = - 0.50 to
0.32

CI = - 0.60 to
1.2

Figure 8

Figure 12

Figure 16

Figure 20

CI = - 1.1 to
0.20

CI = - 0.10 to
0.10

CI = - 0.079 to
0.070

CI = - 0.44 to
0.079

Figure 9

Figure 13

Figure 17

Figure 21

CI = - 0.39 to
0.53

CI = - 0.37 to
0.27

CI = - 0.64 to 1.0

CI = - 0.57 to
1.1

ATGT

AT

GT3
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Table 4. Confidence Intervals (CI) for 13-HODE, 15-HETE, 12-HETE, and 5-HETE in
HCT-116 Cells Obtained at 95% Confidence Level
Vitamin E
isoforms

13-HODE

15-HETE

12-HETE

5-HETE

GT

Figure 23

Figure 28

Figure 32

Figure 36

CI = - 0.23 to
0.18

CI = -0.043 to
0.22

CI = - 0.44 to
0.47

CI = - 0.57 to
2.14

Figure 24

Figure 29

Figure 33

Figure 37

CI = - 0.31 to
0.10

CI = - 0.19 to
0.15

CI = 0.0072 to
0.94

CI = - 0.47 to
1.7

Figure 24

Figure 30

Figure 34

Figure 38

CI = - 0.19 to
0.071

CI = - 0.081 to
0.024

CI = - 0.83 to
0.04

CI = -0.44 to
0.079

Figure 26

Figure 31

Figure 35

Figure 39

CI = 0.031 to
0.23

CI = - 0.083 to
0.18

CI = - 0.0079 to
0.88

CI = - 0.41 to
4.0

ATGT

AT

GT3
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Table 5. Probability Test Values (p-value or p) of 13-HODE, 15-HETE, 12-HETE, and
5-HETE in the Media of HCT-116 Cells Obtained at 95% Confidence Level
Vitamin E
isoforms

13-HODE

15-HETE

12-HETE

5-HETE

GT

Figure 6

Figure 10

Figure 14

Figure 18

p = 0.038

p = 0.36

p = 0.0014

p = 0.49

Figure 7

Figure 11

Figure 15

Figure 19

p = 0.045

p = 0.25

p = 0.30

p = 0.24

Figure 8

Figure 12

Figure16

Figure 20

p = 0.067

p = 0.49

p = 0.45

p = 0.072

Figure 9

Figure 13

Figure 17

Figure 21

p = 0.37

p = 0.47

p = 0.29

p = 0.24

ATGT

AT

GT3

Table 6. Probability Test Values (p-value or p) of 13-HODE, 15-HETE, 12-HETE, and
5-HETE in HCT-116 Cells Obtained at 95% Confidence Level
Vitamin E
isoforms

13-HODE

15-HETE

12-HETE

5-HETE

GT

Figure 23

Figure 28

Figure 32

Figure 36

p = 0.39

p = 0.081

p = 0.47

p = 0.11

Figure 24

Figure 29

Figure 33

Figure 37

p = 0.14

p = 0.39

p = 0.024

p = 0.11

Figure 25

Figure 30

Figure 34

Figure 38

p = 0.16

p = 0.12

p = 0.034

p = 0.037

Figure 26

Figure 31

Figure 35

Figure 39

p = 0.0092

p = 0.21

p = 0.027

p = 0.046

ATGT

AT

GT3
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Table 7. Confidence Intervals (CI) and Probability Test Values (p-value or p) for the
Amount of 13-HODE in HCT-116 Cells Using ELISA Method.
Vitamin E isoforms

13-HODE

GT

Figure 22
p = 0.096
CI = -0.033 to 0.0081

GT3

Figure 27
p = 0.015
CI = 0.0039 to 0.052
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Appendix B
Buffers and Solutions
1. PBS: Prepared using 8 g sodium chloride, 0.2 g potassium chloride,
0.2 g potassium dihydrogen phosphate, and 1.15 g disodium hydrogen
phosphate in 1 L of distilled water.
2. Lysis buffer: Prepared using 98 mL of PBS, 1 mL of 10% triton X-100, 1 mL of
10% sodium dodecyl sulphate.
3. Calcium chloride (1 mM): 0.0147 g of calcium chloride dihydrate was weighed
and dissolved in 100 mL of PBS.
4. Calcium ionophore (1 mM): 0.001 g of calcium ionophore was dissolved in 2 mL
of PBS solution.
5. 0.2 N HCl: 1.65 mL of 12.1 N HCl was diluted to 100 mL with deionised water.
6. Wash Buffer: 5 mL of the supplied concentrate was diluted with 95 mL of
deionized water.
7. Conjugate (1:10) dilution: 50 µL of the supplied conjugate was diluted with 450
mL of standard diluents (assay buffer).
8. Arachidonic acid (10000 µM): 10000 µM was prepared from 0.8210 M
arachidonic acid stock solution in ethanol.
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Appendix C
List of Instruments
1.

HP- 8452A diode array spectrophotometer

2.

UV-VIS spectrophotometer plate reader (Molecular devices, Spectra Max Plus
384).

3.

Shimadzu IT-TOF LC/MS/MS
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Appendix D
Lists of Abbreviations
AA

- arachidonic acid

AA-861

- 2-(12-Hydroxydodecane-5, 10-diynyl)-3, 5, 6-trimethyl-p
benzoquinone

AT

- alpha tocopherol

AT3

- alpha tocotrienol

ATGT

- alpha tocopherol – gamma tocopherol mixture

Bcl-2

- B-cell lymphoma 2

BHPP

- N-benzyl-N-hydroxy-5-phenylpentamide

BRL49653

- rosiglitazone

Cdk

- cyclin-dependent kinases

COX-2

- cyclooxygenase-2

DNA

- deoxyribonucleic acid

ELISA

- enzyme-linked immunosorbent assay

FBS

- fetal bovine serum

G1

- gap 1

G2

- gap 2

GT

- gamma tocopherol
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GT3

- gamma tocotrienol

HCl

- hydrochloric acid

HETE

- hydroxyeicosatetraenoic acid

HODE

- hydroxyoctadecadienoic acid

13-HODE

-13-hydroxyoctadecadienoic acid

15-HETE

-15-hydroxyoctadecadienoic acid

12-HETE

-12-hydroxyeicosatetraenoic acid

IT-TOF

- ion trap time of fight

IU

- international unit

Kg

- kilogram

LOX

- lipoxygenase

LC/MS/MS

- liquid chromatography/tandem mass spectrometry

LA

- Linoleic acid

µM

- micromolar

Max

- maximum

M

- mitotic

MD

- Maryland

mg

- milligram

min

- minutes
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mL

- milliliter

mM

- millimolar

MK 886

- 1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-α,αdimethyl-5-(1-methylethyl)-1H-indole-2-propanoic acid

M

- micromolar

nM

- nanometer

NSAID

- non-steroidal anti-inflammatory drug

NY-

-New York

P

- protein

PAH

- polycyclic aromatic hydrocarbons

PBS

- phosphate buffered saline

PG

- prostaglandins

PPAR γ-

- peroxisome proliferator-activated receptor γ

R

- rectus

RB

- retinoblastoma

S

- synthesis

UV-VIS

- ultraviolet-visible
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